Flavio A Cadegiani Selected Research

Overtraining Syndrome

1/2021	Effects of Overtraining Status on the Cortisol Awakening Response-Endocrine and Metabolic Responses on Overtraining Syndrome (EROS-CAR).
1/2021	Novel Markers of Recovery From Overtraining Syndrome: The EROS-LONGITUDINAL Study.
8/2019	Basal Hormones and Biochemical Markers as Predictors of Overtraining Syndrome in Male Athletes: The EROS-BASAL Study.
6/2019	Clinical and biochemical characteristics of high-intensity functional training (HIFT) and overtraining syndrome: findings from the EROS study (The EROS-HIFT).
1/2019	Novel causes and consequences of overtraining syndrome: the EROS-DISRUPTORS study.
1/2019	Novel insights of overtraining syndrome discovered from the EROS study.
1/2019	Inter-correlations Among Clinical, Metabolic, and Biochemical Parameters and Their Predictive Value in Healthy and Overtrained Male Athletes: The EROS-CORRELATIONS Study.
8/2018	Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: Results of the EROS study (EROS-PROFILE).
7/2018	Hormonal response to a non-exercise stress test in athletes with overtraining syndrome: results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) - EROS-STRESS.
12/2017	Hypothalamic-Pituitary-Adrenal (HPA) Axis Functioning in Overtraining Syndrome: Findings from Endocrine and Metabolic Responses on Overtraining Syndrome (EROS)-EROS-HPA Axis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Flavio A Cadegiani Research Topics

Disease

11	Overtraining Syndrome 01/2021 - 01/2017
9	COVID-19 03/2022 - 01/2020
9	Fatigue 02/2021 - 08/2016
3	Obesity 10/2020 - 01/2017
2	Alopecia (Baldness) 02/2021 - 02/2021
2	Hypertension (High Blood Pressure) 10/2020 - 09/2020
1	Infections 01/2022
1	Anosmia 02/2021
1	Sleep Deprivation 01/2021
1	Severe Acute Respiratory Syndrome 10/2020
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020
1	Dehydration (Water Stress) 08/2018
1	Hypoglycemia (Reactive Hypoglycemia) 07/2018
1	Morbid Obesity 01/2017
1	Inflammation (Inflammations) 01/2017
1	Weight Loss (Weight Reduction) 01/2017
1	Dumping Syndrome (Syndrome, Dumping) 01/2016

Drug/Important Bio-Agent (IBA)

11	2-toluenesulfonamide (OTS)IBA 01/2021 - 01/2017
4	AndrogensIBA 12/2021 - 09/2020
3	Androgen Receptors (Androgen Receptor)IBA 02/2021 - 10/2020
3	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2021 - 08/2016
3	Spironolactone (Aldactone)FDA LinkGeneric 10/2020 - 01/2020
2	Ivermectin (Mectizan)FDA Link 03/2022 - 01/2022
2	Pharmaceutical PreparationsIBA 12/2021 - 09/2020
2	proxalutamideIBA 12/2021 - 02/2021
2	Androgen Receptor AntagonistsIBA 02/2021 - 02/2021
2	Dutasteride (Avodart)FDA Link 02/2021 - 09/2020
2	Serine Proteases (Serine Protease)IBA 02/2021 - 10/2020
2	Hormones (Hormone)IBA 10/2020 - 08/2019
2	Antihypertensive Agents (Antihypertensives)IBA 10/2020 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 08/2019 - 01/2019
1	Proteins (Proteins, Gene)FDA Link 02/2021
1	Azithromycin (Zithromax)FDA LinkGeneric 02/2021
1	nitazoxanide (NTZ)FDA Link 02/2021
1	Androgen Antagonists (Antiandrogens)IBA 02/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	AngiotensinsIBA 10/2020
1	MineralocorticoidsIBA 10/2020
1	angiotensin I (1-7)IBA 10/2020
1	Angiotensin IIIBA 10/2020
1	nafamostatIBA 09/2020
1	GlucocorticoidsIBA 09/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 09/2020
1	Cysteine (L-Cysteine)FDA Link 09/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2020
1	Eplerenone (Inspra)FDA LinkGeneric 09/2020
1	Finasteride (Propecia)FDA LinkGeneric 09/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2020
1	camostatIBA 09/2020
1	Angiotensin Receptor AntagonistsIBA 09/2020
1	LipidsIBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2016
1	Acarbose FDA LinkGeneric 01/2016

Therapy/Procedure

5	Therapeutics 02/2021 - 08/2016
1	Length of Stay 12/2021
1	Secondary Prevention 02/2021
1	Artificial Respiration (Mechanical Ventilation) 09/2020
1	Obesity Management 01/2017
1	Bariatric Surgery 01/2017
1	Drug Therapy (Chemotherapy) 01/2017